Evidence map›Paper›PMID 24317174›Full record

ArticleJournal of the National Cancer Institute2013

Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations.

Hongmei Nan, Teppei Morikawa, Miia Suuriniemi, Yu Imamura, Lillian Werner, Aya Kuchiba, Mai Yamauchi, David J Hunter, Peter Kraft, Edward L Giovannucci and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 6 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 6 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review.International journal of molecular sciences · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Colorectal Cancer Chemoprevention: A Dream Coming True?International journal of molecular sciences · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Hongmei NanAffiliations of authors: Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD (HN); Channing Division of Network Medicine, Department of Medicine (HN, DJH, ELG, CSF, ATC) and Department of Epidemiology (DJH, PK, ELG, SO), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Center for Molecular Oncologic Pathology (TM, YI, AK, MY, SO), Department of Medical Oncology (TM, MS, YI, AK, MY, CSF, SO, MLF), and Department of Biostatistics and Computational Biology (LW), Dana-Farber Cancer Institute, Boston, MA; Department of Epidemiology (DJH, ELG, SO) and Department of Nutrition, Harvard School of Public Health, Boston, MA (DJH, ELG); Broad Institute, Program in Medical and Population Genetics, Cambridge, MA (MLF); Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA (ATC).
Teppei Morikawa
Miia Suuriniemi
Yu Imamura
Lillian Werner
Aya Kuchiba
Mai Yamauchi
David J Hunter
Peter Kraft
Edward L Giovannucci
Charles S Fuchs
Shuji Ogino
Matthew L Freedman
Andrew T Chan
University of Maryland, Baltimore · USBrigham and Women's Hospital · USBroad Institute · USDana-Farber Cancer Institute · USHarvard University · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SICINSKA, · 2007 to 2023
$33.2M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
Impact of Celecoxib and Inflammation on Survival in Stage III Colon CancerR01CA169141 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2013 to 2018
$3.9M
Epigenetic Events and Colorectal Cancer EpidemiologyR01CA151993 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2010 to 2014
$2.6M
Mentored Patient-Oriented Research in Digestive DiseasesK24DK098311 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2013 to 2017
$930k
NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA169141NIDDK NIH HHS K24 DK098311
6 · The paper itself

Abstract

backgroundRegular aspirin use reduces the risk for colorectal cancer (CRC), possibly through inhibition of WNT/cadherin-associated protein β1 (CTNNB1 or β-catenin) signaling. The single nucleotide polymorphism (SNP) rs6983267 on chromosome 8q24 is a CRC susceptibility locus that affects binding activity of transcription factor 7 like-2 (TCF7L2) to CTNNB1, thereby altering expression of target oncogenes, including MYC.

methodsWe evaluated regular aspirin use and CRC risk according to genotypes of SNP rs6983267 and CTNNB1 expression status in two prospective case-control studies (840 CRC case patients and 1686 age- and race-matched control subjects) nested within the Nurses' Health Study and the Health Professionals Follow-up Study. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression models. All statistical tests were two-sided.

resultsA lower risk of CRC was associated with regular aspirin use and the T allele of rs6983267. The effect of aspirin was confined to individuals with protective T allele of rs6983267 (additive matching factors-adjusted OR for T allele = 0.83; 95% CI = 0.74 to 0.94; P trend = .002; P interaction = .01). Additionally, the T allele of rs6983267 was associated with a reduced expression of MYC oncogene (P trend = .03). Moreover, among individuals with protective T allele, the effect of regular aspirin use was limited to those with positive nuclear CTNNB1 expression. In a functional analysis, in vitro treatment of LS174T cells (a cell line heterozygous for rs6983267) with aspirin was statistically significantly associated with higher G/T allelic ratio of TCF7L2 immunoprecipitated DNA (P = .03).

conclusionsOur results support an influence of aspirin on WNT/CTNNB1 signaling and suggest that aspirin chemoprevention may be tailored according to rs6983267 genotype.

Indexed as

Chromosomes, Human, Pair 8Polymorphism, Single NucleotideAdultAgedAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalAspirinbeta CateninCase-Control StudiesChromatin ImmunoprecipitationColorectal NeoplasmsDrug Administration ScheduleFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalAspirinbeta CateninCTNNB1 protein, humanTCF7L2 protein, humanTranscription Factor 7-Like 2 ProteinWnt Proteins

Identifiers

PMID24317174
PMCPMC3866156
OpenAlexW2161483608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.